Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (BSGM) on March 24, 2020. The report details a material definitive agreement entered into by NeuroClear Technologies, Inc., a majority-owned subsidiary of BioSig, with Trek Therapeutics, PBC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The transaction involves a combination of consideration including upfront cash payments, milestone payments, and shares of Trek's common stock (potentially up to 10% of NeuroClear's outstanding equity), alongside potential sublicense fees.
Material Changes
The primary material change is the acquisition of specific assets from Trek Therapeutics, including:
- Certain pharmaceutical compounds.
- An assignment and license agreement with Vertex Pharmaceuticals Incorporated.
- Intellectual property, patents, trademarks, and technical know-how related to the compounds.
- Regulatory materials, inventory, raw materials, and active pharmaceutical ingredients.
- Assumption of liabilities under the assigned license agreement and other liabilities arising post-closing.
Outlook, Risks, and Management Commentary
Management announced the agreement via a press release on March 25, 2020. The transaction structure includes contingent payments (milestones and sublicense fees), indicating future financial obligations dependent on the commercial success or further licensing of the acquired assets. The filing does not explicitly list new risks or contingencies beyond the standard obligations of the asset purchase.
Investor Verification Checklist
- Verify the exact cash amount of the upfront payment and the specific milestones triggering future payments.
- Confirm the valuation of the Trek common stock to be issued and its impact on NeuroClear's equity dilution.
- Review the terms of the assigned license agreement with Vertex Pharmaceuticals Incorporated.
- Assess the regulatory status of the acquired compounds and the timeline for potential commercialization.
- Examine the specific liabilities assumed by NeuroClear under the agreement.